HC Wainwright Issues Pessimistic Forecast for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price target cut by analysts at HC Wainwright from $8.00 to $5.50 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 374.14% from the stock’s current price. HC Wainwright also issued estimates for Plus Therapeutics’ FY2029 earnings at $0.95 EPS.

Several other equities analysts also recently commented on PSTV. D. Boral Capital initiated coverage on Plus Therapeutics in a research report on Monday, March 17th. They set a “buy” rating and a $9.00 target price for the company. Ascendiant Capital Markets decreased their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.

Plus Therapeutics Stock Performance

Shares of PSTV stock opened at $1.16 on Friday. The firm has a fifty day moving average of $1.11 and a 200-day moving average of $1.24. The stock has a market cap of $6.84 million, a price-to-earnings ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million. On average, sell-side analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.